论文部分内容阅读
目的观察超声透药对慢性肾脏病CKD3-4期患者的临床疗效。方法将60例慢性肾脏病CKD3-4期患者分为观察组和对照组,2组均给予基础治疗,观察组加用超声药物透入治疗,14天为1个疗程,观察2组治疗前后中医症候评分、血肌酐、尿素氮、尿酸、血红蛋白等指标变化。结果观察组总有效率86.7%,对照组63.3%,2组间差异有统计学意义(P<0.05)。治疗后2组中医症候评分、血肌酐、尿素氮、尿酸均较治疗前有所下降,差异有统计学意义(P<0.05),其中在中医症候评分、血肌酐、尿酸的改善方面观察组优于对照组,差异亦有统计学意义(P<0.05)。结论超声透药能够改善慢性肾脏病CKD3-4期患者的临床症状,更好地降低血肌酐、尿酸。
Objective To observe the clinical effect of ultrasonic dialysis on chronic kidney disease patients with stage CKD3-4. Methods Sixty CKD patients with CKD stage 3-4 were divided into two groups: observation group and control group. Both groups were given basic treatment. The observation group was treated with percutaneous transnasal ultrasound. One course of treatment was 14 days. Two groups were observed before and after treatment Symptom score, serum creatinine, urea nitrogen, uric acid, hemoglobin and other indicators change. Results The total effective rate was 86.7% in the observation group and 63.3% in the control group, with significant difference between the two groups (P <0.05). After treatment, TCM syndrome scores, serum creatinine, blood urea nitrogen, and uric acid in both groups were significantly lower than those before treatment (P <0.05), of which TCM syndrome score, serum creatinine and uric acid were improved In the control group, the difference was also statistically significant (P <0.05). Conclusion Ultrasound can improve the clinical symptoms of patients with chronic kidney disease CKD3-4 stage, and better reduce serum creatinine, uric acid.